

Vanucizumab ELISA Kit

Summary

| | |
|------------------------------|---|
| Catalog No. | KDA42303 |
| Alternative Names | RG-7221, RG7221, RO5520985, CAS: 1448221-05-3 |
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Detection method | Colorimetric |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 0.156 µg/ml |
| Range | 0.31-5 µg/mL |
| Recovery | 80-120% |
| Shipping | 2-8 °C |
| Note | For Research Use Only. |

Background

Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a

Recombinant Proteins & Antibodies

phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.

Precision

CV<20%

Data Image
